Andere Sprachen InnoCan Pharma Corporation Deutsche Boerse AG

Aktien

A2PSPW

CA45783P1027

IP4

Markt geschlossen - Deutsche Boerse AG Andere Börsenplätze 21:08:53 13.06.2024			% 5 Tage	% 1. Jan.
0,1815 ^EUR	-5,71 %		-6,68 %	-7,02 %

27.05.	InnoCan Pharma Corporation meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
27.05.	Innocan Pharma meldet Ergebnisse für das erste Quartal 2024 mit einem Umsatzwachstum von mehr als dem 4fachen auf $6,8 Millionen	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs	11.06.
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs	11.06.
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	27.05.
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	27.05.
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million	27.05.
Refile: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21.05.
InnoCan Pharma Brief: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21.05.
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21.05.
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	09.05.
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	09.05.
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	22.04.
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	22.04.
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M	01.04.
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	25.03.
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval	25.03.
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.	25.03.
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million	15.03.
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding	14.03.
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen InnoCan Pharma Corporation Deutsche Boerse AG

Aktien

A2PSPW

CA45783P1027

IP4

Andere Sprachen

Filter